Project DEEP aims to revolutionize early detection and prevention of cardiometabolic diseases.
Withings announced a $22.5 million investment from the France 2030 initiative to launch Project DEEP (DEvice as a hEalth Prevention platform). This groundbreaking initiative leverages AI and non-invasive medical devices to address the global challenge of cardiometabolic diseases.
Pioneering Preventive Healthcare
Project DEEP focuses on developing advanced devices for early detection and prevention of conditions like:
- Diabetes
- Hypertension
- Atrial fibrillation (AFib)
- Neuropathies
By enabling early interventions, Withings aims to mitigate complications such as stroke, myocardial infarction, and amputations, reducing strain on healthcare systems.
“With the surge in cardiometabolic diseases, technological innovation and AI research are pivotal in transitioning to preventive care,” said Eric Carreel, chair and founder of Withings.
Strengthening a Connected Ecosystem
Withings already offers a portfolio of smart health devices, including scales, blood pressure monitors, sleep analyzers, and urine analyzers. By integrating AI with these tools, Project DEEP aims to deliver personalized, proactive care tailored to individual health profiles.
France 2030’s Vision for Innovation
Supported by the $56.6 billion France 2030 initiative, this project positions Withings as a global leader in digital health transformation. Over the next five years, Project DEEP will drive Withings’ R&D efforts, enhancing existing products and paving the way for future innovations.
Follow MEDWIRE.AI for updates on groundbreaking MedTech initiatives transforming healthcare worldwide.
